Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Head Neck. 2022 Sep;44(9):2040-2045. doi: 10.1002/hed.27085.
There is limited evidence supporting the use of taxane-based chemotherapy combined with cetuximab to treat recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). This retrospective study aimed to explore treatment efficacy and safety in a first-line setting.
Fifty-nine patients received ≤6 cycles of combined cetuximab, platinum compounds, and taxane (median follow-up, 352 days). Kaplan-Meier survival curves were constructed.
The median patient age was 54 years (23-75 years; 50 males and 9 females). The most common distant metastatic site was the lung. Patients received ≥2 cycles chemotherapy (33 [55.9%] received cetuximab, paclitaxel, and carboplatin; 21 [35.5%] received cetuximab maintenance; median progression-free survival, 7 months; overall survival, 12 months). The most common hematological toxicity was Grade 3 or 4 neutropenia, which was successfully managed through growth-stimulating factors and dose modifications. No treatment-associated deaths occurred.
Combined cetuximab, platinum, and taxane is effective and tolerable in R/M HNSCC.
有有限的证据支持使用紫杉烷类化疗联合西妥昔单抗治疗复发性/转移性头颈部鳞状细胞癌（R/M HNSCC）。本回顾性研究旨在探讨一线治疗中的疗效和安全性。
59 例患者接受了≤6 个周期的西妥昔单抗、铂类化合物和紫杉烷联合治疗（中位随访 352 天）。绘制 Kaplan-Meier 生存曲线。
患者的中位年龄为 54 岁（23-75 岁；50 名男性和 9 名女性）。最常见的远处转移部位是肺部。患者接受了≥2 个周期的化疗（33 例[55.9%]接受了西妥昔单抗、紫杉醇和卡铂；21 例[35.5%]接受了西妥昔单抗维持治疗；中位无进展生存期为 7 个月；总生存期为 12 个月）。最常见的血液学毒性是 3 级或 4 级中性粒细胞减少症，通过生长刺激因子和剂量调整可成功治疗。没有与治疗相关的死亡事件发生。
西妥昔单抗、铂类和紫杉烷联合治疗 R/M HNSCC 是有效且耐受良好的。
